• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Clonal Hematopoiesis Alters Solid Tumor Microenvironments Across Tissue and Lineage Contexts

by
November 13, 2026
in Biology
Reading Time: 6 mins read
0
Clonal Hematopoiesis Alters Solid Tumor Microenvironments Across Tissue and Lineage Contexts

Clonal Hematopoiesis Alters Solid Tumor Microenvironments Across Tissue and Lineage Contexts

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Clonal hematopoiesis introduces an active hematopoietic component into the molecular and immune architecture of solid tumors, requiring careful distinction between cancer-cell genetics and infiltrating immune alterations. Somatic variants detected within solid-tumor specimens or circulating cell-free DNA do not automatically originate from malignant cells. Instead, clonal expansions arising in blood-forming stem cells can populate the stroma and immune compartments of tumors, introducing nonmalignant mutations that masquerade as oncogenic alterations. In a comprehensive review published in Frontiers in Cell and Developmental Biology, researchers synthesize findings across clinical cohorts, tissue localization studies, and experimental model systems to establish a rigorous framework for evaluating clonal hematopoiesis. The analysis reveals that the biological and clinical meaning of a somatic variant fundamentally depends on whether it is identified in peripheral blood, circulating plasma, or tumor tissue, which specific immune lineage carries it, and the precise timing of sampling relative to anticancer therapies.

Solid tumors are complex multicellular structures composed of malignant cells intermixed with nonmalignant stroma, vascular elements, and infiltrating leukocytes. Standard high-throughput sequencing pipelines applied to unsorted bulk tumor samples capture DNA from every cell type present in the biopsy. When somatic variants are recovered from this cellular mixture, treating every alteration as a tumor driver leads to substantial diagnostic misinterpretation. Paired leukocyte sequencing has demonstrated that variants in genes such as KRAS, JAK2, TP53, and various DNA repair pathways, which might otherwise be attributed to the cancer genome, frequently trace back to nonmalignant hematopoietic clones. For instance, misidentifying a blood-derived mutation in a DNA repair gene as a primary tumor defect could inappropriately guide targeted therapies, while persistent hematopoietic variants in plasma can be misread as residual cancer following surgical resection or systemic treatment. Establishing the true compartment of origin through matched leukocyte and tissue controls represents an immediately actionable safeguard against erroneous oncologic management.

Evaluating cell-free DNA in plasma introduces further interpretative challenges, because circulating cell-free DNA represents an ever-shifting composite of DNA shed by both solid tumors and hematopoietic cells. Circulating tumor DNA constitutes only a fraction of total cell-free DNA, and its abundance fluctuates dynamically in response to cytotoxic regimens, radiation, and surgical interventions. In longitudinal cohorts, such as patients with ovarian cancer transitioning from platinum chemotherapy to PARP inhibitor maintenance, putative clonal hematopoiesis signals frequently display an apparent increase in variant allele fraction. Rather than reflecting true biological expansion of the blood clone, this apparent rise often stems from the unmasking effect caused by a precipitous decline in tumor-derived circulating DNA. Parallel observations in lung cancer cohorts highlight cases where tumor-specific alterations vanish during effective therapy while persistent hematopoietic KRAS variants remain stable in circulation. Accurate interpretation of serial liquid biopsies therefore mandates deconstructing the individual biological sources contributing to plasma DNA before drawing conclusions regarding tumor response, emerging drug resistance, or hematologic clonal dynamics.

Where paired leukocyte analysis is unavailable, computational classifiers and orthogonal profiling techniques have been developed to triage uncertain somatic variants. Supervised origin classifiers utilizing random forest and logistic regression architectures, trained against source-labeled validation cohorts, have achieved areas under the receiver operating characteristic curve of 0.90 in distinguishing hematopoietic from tumor-derived variants. Dedicated multifeature models incorporating variant allele fractions, clinical covariates, and fragmentomic properties have similarly reached areas under the curve of 0.902 in independent validation datasets, heavily outperforming variant allele fraction alone, which achieved an area under the curve of only 0.61 in training sets. Furthermore, fragmentomic profiles capturing fragment length distributions and sequence contexts have demonstrated utility in discriminating clonal hematopoiesis from tumor-derived TP53 variants at very low allele fractions. Orthogonal sampling across multiple non-tumor biofluids, including saliva, peripheral blood mononuclear cells, and plasma, provides additional confidence for low-frequency calls, although diagnostic sensitivity-specificity trade-offs and variable cross-platform calibration still leave direct leukocyte sequencing as the definitive gold standard.

Beyond serving as an analytical confounder in genomic sequencing, clonal hematopoiesis exerts tangible biological effects when mutation-bearing leukocytes actively infiltrate solid tumors. Bulk sequencing can confirm the presence of blood-defined variants within tumor tissue, a phenomenon termed tumor-infiltrating clonal hematopoiesis, but bulk detection cannot identify the specific carrier cell type or delineate its local spatial orientation. In paired blood-tumor pan-cancer investigations, clonal hematopoiesis variants detected in bulk tumor tissue have been associated with distinct inflammatory transcriptional programs and altered clinical survival. In multiregion studies of early-stage non-small cell lung cancer, tumor-infiltrating clones exhibited stronger prognostic associations with disease recurrence than clones strictly confined to the peripheral circulation. Similarly, historical analyses in breast cancer identified identical mutant clones within tumor-infiltrating leukocytes years before patients subsequently developed therapy-related myeloid neoplasms. These observations establish that hematopoietic clones actively enter the neoplastic niche, highlighting that tissue presence marks a distinct biological state that cannot be inferred from peripheral blood testing alone.

The biological consequences of clonal hematopoiesis within tumor microenvironments are strictly shaped by the specific driver gene and the immune lineage harboring the mutation. Broad proteomic screens in large biobank cohorts indicate that mutations in ASXL1 and TET2 drive divergent systemic signaling profiles, with TET2 correlating with inflammatory pathways while ASXL1 is linked to metabolic alterations and predicted reductions in interleukin-6 and STAT3 signaling. Single-cell multi-omic profiling reveals that TET2 mutations are predominantly enriched within mature myeloid lineages, where they alter monocyte differentiation and enhance inflammatory signaling cascades. In experimental breast cancer models, Tet2-mutant hematopoiesis actively accelerated primary tumor growth and enhanced pulmonary metastasis, whereas Dnmt3a-mutant hematopoiesis failed to produce comparable malignant phenotypes. Conversely, the phenotypic consequences of ASXL1 mutations depend exquisitely on cellular context: systemic conditional models demonstrated that mutant T cells drove tumor acceleration accompanied by reduced overall T-cell infiltration, whereas perturbation of Asxl1 within antigen-specific CD8 T cells preserved a stem-like state that enhanced tumor control under immune checkpoint blockade.

Mechanistic investigations in solid-tumor models show that TET2-mutant myeloid cells directly reprogram the local immune microenvironment by altering macrophage antigen presentation and CD8 T-cell cross-priming. In preclinical models, this enhanced immune engagement translated into improved therapeutic sensitivity to immune checkpoint inhibition, echoing survival correlations observed in human clinical subsets. However, this therapeutic benefit requires coordinated interactions across multiple immune lineages, as the enhanced checkpoint response was entirely abrogated when Tet2 inactivation was restricted solely to myeloid cells or T cells, or when the mutant hematopoietic fraction dropped to twenty percent. Other model systems complicate broad generalizations; in murine lung adenocarcinoma, TET2-mutant hematopoiesis reorganized pulmonary lymphoid aggregates and modulated local leukocyte composition without producing a statistically significant change in primary tumor volume. These contrasting findings underscore that an inflammatory tissue profile does not dictate a uniform direction for tumor development or treatment response across different anatomical locations.

Clinical evaluations of immune checkpoint inhibitors further demonstrate that aggregate clonal hematopoiesis cannot serve as a reliable, generalized predictive biomarker of therapeutic response. Real-world retrospective analyses linking clonal hematopoiesis to checkpoint inhibitor treatment duration are heavily vulnerable to immortal-time bias and confounding by therapy line, as treatment duration reflects patient tolerability and reasons for cessation rather than progression-free or overall survival. Cohorts of metastatic gastrointestinal cancers have demonstrated that neither aggregate clonal hematopoiesis nor putative driver subsets correlate with progression-free survival during immune checkpoint blockade or standard first-line chemotherapy. Furthermore, serial sequencing demonstrates that immune checkpoint inhibitors do not induce the rapid, selective clonal expansion characteristic of DNA-damaging cytotoxic agents, although extended treatment windows can allow slow enlargement of specific DNMT3A- or TET2-mutant clones among patients who achieve prolonged clinical benefit. Consequently, evaluating clonal hematopoiesis as a predictive marker requires testing specific genotypes and cell states within prospective, randomized treatment comparisons rather than relying on binary presence-absence metrics.

Therapy-associated toxicity profiles linked to clonal hematopoiesis similarly diverge across specific organ systems and drug classes rather than representing a generalized inflammatory syndrome. Prospective cardio-oncology registries have identified that clonal hematopoiesis of indeterminate potential carries a significantly elevated risk of immune checkpoint inhibitor-associated myocarditis, yielding an adjusted hazard ratio of 2.74 with a ninety-five percent confidence interval of 1.44 to 5.22 after accounting for competing risks. In sharp contrast, prospective cancer cohorts found no independent association between clonal hematopoiesis and either arterial or venous thrombosis, and broad oncology analyses demonstrate no aggregate correlation with overall high-grade immune-related adverse events. Distinct drug-specific toxicities are also evident in HER2-targeted therapy, where clonal hematopoiesis with an allele fraction of at least one percent conferred an adjusted subdistribution hazard ratio of 1.91 for cardiac dysfunction among trastuzumab-treated breast cancer patients across two independent cohorts. In anthracycline therapy, clinical cardiotoxicity associations were mechanistically corroborated by preclinical models showing that TP53-mutant hematopoiesis aggravates doxorubicin-induced cardiomyopathy through a cytotoxic, neutrophil-mediated inflammatory response.

Systemic cancer therapies actively reshape the hematopoietic fitness landscape, exerting selective pressures that dictate which clonal trajectories emerge over time. DNA-damaging chemotherapy, radiotherapy, and targeted radioligand therapies preferentially enrich clones bearing mutations in DNA damage response genes, most notably TP53 and PPM1D, while DNMT3A- and TET2-mutant clones exhibit no comparable post-treatment expansion. Long-term follow-up demonstrates that the likelihood of clonal emergence depends on baseline clonal repertoires, cumulative drug exposure, and patient-specific DNA repair capacities, with pretreatment TP53 mutations linked to an increased risk of therapy-related myeloid neoplasms following platinum and PARP inhibitor regimens. Understanding these divergent evolutionary trajectories requires rigorous analytical thresholds capable of separating true biological growth from technical assay variation, biological drift, and shifting plasma compositions. Advancing the clinical translation of clonal hematopoiesis will ultimately require connecting source-attributed blood variants to spatial, single-cell functional measurements within tumors, evaluating calibrated, organ-specific risk models rather than seeking a singular, universal threshold across all oncologic applications.

Subject of Research: Clonal hematopoiesis and its biological roles within solid tumor microenvironments

Article Title: Clonal hematopoiesis in solid tumors: mutant hematopoietic cells as a tumor-microenvironment component across source, lineage and treatment

Article References: Su, H., Tang, J., & Li, L. (2026). Clonal hematopoiesis in solid tumors: mutant hematopoietic cells as a tumor-microenvironment component across source, lineage and treatment. Frontiers in Cell and Developmental Biology, 14, Article 1982408. https://doi.org/10.3389/fcell.2026.1982408

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1982408

Keywords: clonal hematopoiesis, solid tumors, tumor microenvironment, cancer genomics, cell-free DNA, immunotherapy, variant allele fraction, myeloid cells, Clonal, hematopoiesis, solid, tumors

News Source: Nathaniel Bowman. (November 13, 2026). Clonal Hematopoiesis Alters Solid Tumor Microenvironments Across Tissue and Lineage Contexts. Scienmag.

Tags: cancer genomicscell-free DNAclonalclonal hematopoiesishematopoiesisimmunotherapyMyeloid Cellssolidsolid tumorstumor microenvironmenttumorsvariant allele fraction
Share12Tweet7Share2ShareShareShare1

Related Posts

Engineered Male Sterility Systems Advance Scalable Hybrid Seed Production in Maize

Engineered Male Sterility Systems Advance Scalable Hybrid Seed Production in Maize

November 16, 2026
YOD1 Stabilization Promotes Bcl-xL-Dependent Enzalutamide Resistance in Prostate Cancer Models

YOD1 Stabilization Promotes Bcl-xL-Dependent Enzalutamide Resistance in Prostate Cancer Models

November 16, 2026

Fermented Camel Milk Peptides Show Potential to Combat Inflammation and Diabetes

November 16, 2026

McDag Indexes Maximal Common Subsequences Across Multiple Genomic Sequences in Minutes

November 16, 2026

POPULAR NEWS

  • Childhood Plasma miRNAs Indicate Neurodevelopmental Delay Linked to Prenatal Alcohol Exposure

    Childhood Plasma miRNAs Indicate Neurodevelopmental Delay Linked to Prenatal Alcohol Exposure

    29 shares
    Share 12 Tweet 7
  • OCD Patients Show Heightened Sensitivity to Local Evidence Despite Lower Overall Confidence

    29 shares
    Share 12 Tweet 7
  • Prenatal Anxiety and Depression Predict Distinct Infant Cerebellar Asymmetry Patterns

    29 shares
    Share 12 Tweet 7
  • Probing combined with platelet-rich plasma improved moderate-to-severe meibomian dysfunction in trial

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Lifelong Serotonin Deficiency Delays Maturation and Alters Sociability in Rats

AI Guidance Enables Nonexperts to Capture Diagnostic Echocardiograms in Controlled Settings

Prenatal Stress Shows No Link to Epigenetic Age Acceleration at Birth

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.